teslexivir (BTA074) / Vaxart - LARVOL DELTA

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients (clinicaltrials.gov) - P2; N=218; Active, not recruiting; Sponsor: Anaconda Pharma; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar